The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Advances in the classification of agressive myeloma
Nikhil Munshi
• 19 Apr 2018
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. He highlights improvements in our understanding of the biology of the disease, and how the resulting genetic knowledge impacts our stratification of aggresive MM.
